%PDF-1.7 1 0 obj << /Type /Catalog /Outlines 2 0 R /Pages 3 0 R >> endobj 2 0 obj << /Type /Outlines /Count 0 >> endobj 3 0 obj << /Type /Pages /Kids [6 0 R 13 0 R ] /Count 2 /Resources << /ProcSet 4 0 R /Font << /F1 8 0 R /F2 9 0 R /F3 10 0 R >> /ExtGState << /GS1 11 0 R /GS2 12 0 R >> >> /MediaBox [0.000 0.000 595.280 841.890] >> endobj 4 0 obj [/PDF /Text ] endobj 5 0 obj << /Producer (dompdf 3.1.0 + CPDF) /CreationDate (D:20260714123625+00'00') /ModDate (D:20260714123625+00'00') >> endobj 6 0 obj << /Type /Page /MediaBox [0.000 0.000 595.280 841.890] /Parent 3 0 R /Contents 7 0 R >> endobj 7 0 obj << /Length 5886 >> stream 0.000 0.000 0.000 rg BT 35.000 797.842 Td /F1 19.5 Tf [(Treadwell Therapeutics Announces the Appointment of Roger)] TJ ET BT 35.000 774.033 Td /F1 19.5 Tf [(Sidhu, M.D., as Chief Medical Officer)] TJ ET BT 35.000 734.017 Td /F3 14.0 Tf [(Description)] TJ ET BT 35.000 692.827 Td /F1 12.0 Tf [(NEW YORK, Feb. 3, 2023 /CNW/ ?? Treadwell Therapeutics, a clinical-stage, global biotechnology)] TJ ET BT 35.000 678.175 Td /F1 12.0 Tf [(company developing novel, first in class therapeutics for highly aggressive cancers, today announced)] TJ ET BT 35.000 663.523 Td /F1 12.0 Tf [(that it has appointed Roger Sidhu, M.D., as Chief Medical Officer. Dr. Sidhu is a seasoned leader and)] TJ ET BT 35.000 648.871 Td /F1 12.0 Tf [(brings to Treadwell an extensive track record of success over the last 15 years in hematologic and solid)] TJ ET BT 35.000 634.219 Td /F1 12.0 Tf [(tumor oncology research and development with deep translational, clinical and regulatory experience)] TJ ET BT 35.000 619.567 Td /F1 12.0 Tf [(across multiple therapeutic modalities and platforms including small molecules, biologics and cell and)] TJ ET BT 35.000 604.915 Td /F1 12.0 Tf [(gene therapies.)] TJ ET BT 35.000 578.263 Td /F1 12.0 Tf [(??We are excited to welcome Dr. Sidhu to our team as we further the development of our small)] TJ ET BT 35.000 563.611 Td /F1 12.0 Tf [(molecule, biologic and cell therapy pipeline,?)] TJ ET BT 279.776 563.611 Td /F1 12.0 Tf [()] TJ ET BT 283.112 563.611 Td /F1 12.0 Tf [( said Dr. Michael Tusche, Treadwell co-CEO. ??Roger)] TJ ET BT 35.000 548.959 Td /F1 12.0 Tf [(has an extensive track record of success in all aspects of drug development from early to late stage)] TJ ET BT 35.000 534.307 Td /F1 12.0 Tf [(through regulatory approval, as well as being a proven leader and builder. His expertise will be)] TJ ET BT 35.000 519.655 Td /F1 12.0 Tf [(invaluable to our mission of translating novel scientific ideas into first in class medicines for patients in)] TJ ET BT 35.000 505.003 Td /F1 12.0 Tf [(need.?)] TJ ET BT 78.368 505.003 Td /F1 12.0 Tf [()] TJ ET BT 35.000 478.351 Td /F1 12.0 Tf [(??Treadwell??s innovative, first in class pipeline against novel targets in hematologic and solid)] TJ ET BT 35.000 463.699 Td /F1 12.0 Tf [(tumors is driven by world class science and positions the company at the forefront of the next)] TJ ET BT 35.000 449.047 Td /F1 12.0 Tf [(generation of personalized medicines,?)] TJ ET BT 250.436 449.047 Td /F1 12.0 Tf [()] TJ ET BT 253.772 449.047 Td /F1 12.0 Tf [( said Dr. Sidhu. ??I am excited to join the world class team at)] TJ ET BT 35.000 434.395 Td /F1 12.0 Tf [(Treadwell and advance the mission of delivering new medicines for patients with high unmet need in)] TJ ET BT 35.000 419.743 Td /F1 12.0 Tf [(cancer globally.?)] TJ ET BT 131.708 419.743 Td /F1 12.0 Tf [()] TJ ET BT 35.000 393.091 Td /F1 12.0 Tf [(Dr. Sidhu was most recently the Chief Medical Officer at Brooklyn \(now Eterna\) ImmunoTherapeutics, a)] TJ ET BT 35.000 378.439 Td /F1 12.0 Tf [(gene editing and cell therapy company where he advanced multiple novel programs. Previously, Dr.)] TJ ET BT 35.000 363.787 Td /F1 12.0 Tf [(Sidhu served as Executive Vice President and Chief Medical officer at Roivant Sciences. Roger was)] TJ ET BT 35.000 349.135 Td /F1 12.0 Tf [(also the Chief Medical Officer at Cell Design Labs, up until its acquisition by the Gilead subsidiary Kite,)] TJ ET BT 35.000 334.483 Td /F1 12.0 Tf [(where he subsequently served as VP, Clinical Development. Dr. Sidhu also held various roles of)] TJ ET BT 35.000 319.831 Td /F1 12.0 Tf [(increasing responsibility at Amgen where he was an Executive Medical Director in the)] TJ ET BT 35.000 305.179 Td /F1 12.0 Tf [(Hematology/Oncology Therapeutic area with responsibilities that included advancing preclinical and)] TJ ET BT 35.000 290.527 Td /F1 12.0 Tf [(clinical candidates through registration globally. Dr. Sidhu is a Fellow of the Royal College of Physicians)] TJ ET BT 35.000 275.875 Td /F1 12.0 Tf [(and Surgeons of Canada in both internal medicine and medical oncology. He earned his medical)] TJ ET BT 35.000 261.223 Td /F1 12.0 Tf [(degree from Queen??s University in Kingston, Ontario Canada and his Bachelor??s degree in)] TJ ET BT 35.000 246.571 Td /F1 12.0 Tf [(biochemistry from the University of Alberta in Edmonton, Alberta. Dr. Sidhu trained in internal medicine)] TJ ET BT 35.000 231.919 Td /F1 12.0 Tf [(at Queen??s University and medical oncology at the British Columbia Cancer Agency in Vancouver,)] TJ ET BT 35.000 217.267 Td /F1 12.0 Tf [(British Columbia and the Cross Cancer Institute in Edmonton, Alberta.)] TJ ET BT 35.000 186.582 Td /F3 14.0 Tf [(About Treadwell Therapeutics)] TJ ET BT 35.000 157.392 Td /F1 12.0 Tf [(Treadwell Therapeutics is a science driven, clinical-stage, multi-modality biotechnology company)] TJ ET BT 35.000 142.740 Td /F1 12.0 Tf [(developing first-in-class and best-in-class medicines to address unmet needs in patients with cancer.)] TJ ET BT 35.000 128.088 Td /F1 12.0 Tf [(The Company??s internally developed small molecule clinical pipeline includes CFI-400945 \(PLK4)] TJ ET BT 35.000 113.436 Td /F1 12.0 Tf [(inhibitor\), CFI-402257 \(TTK inhibitor\) and CFI-402411 \(HPK1 inhibitor\). The company is also advancing)] TJ ET BT 35.000 98.784 Td /F1 12.0 Tf [(a pre-clinical pipeline of first-in-class antibody and TCR-based cell therapy assets. For more)] TJ ET q 35.000 52.000 m 35.000 53.000 l 585.280 53.000 l 585.280 52.000 l 585.280 50.500 l 35.000 50.500 l W n 0.502 0.502 0.502 RG 1.5 w 0 J [ ] 0 d 35.000 51.250 m 585.280 51.250 l S Q /GS1 gs /GS2 gs 0.000 0.000 0.000 rg BT 44.000 31.732 Td /F1 10.0 Tf [(Page 1)] TJ ET q 44.000 17.080 532.280 12.210 re W n BT 258.180 19.522 Td /F1 10.0 Tf [(Treadwell Therapeutics)] TJ ET Q /GS1 gs /GS2 gs endstream endobj 8 0 obj << /Type /Font /Subtype /Type1 /Name /F1 /BaseFont /Helvetica /Encoding /WinAnsiEncoding >> endobj 9 0 obj << /Type /Font /Subtype /Type1 /Name /F2 /BaseFont /Times-Roman /Encoding /WinAnsiEncoding >> endobj 10 0 obj << /Type /Font /Subtype /Type1 /Name /F3 /BaseFont /Helvetica-Bold /Encoding /WinAnsiEncoding >> endobj 11 0 obj << /Type /ExtGState /BM /Normal /CA 1 >> endobj 12 0 obj << /Type /ExtGState /BM /Normal /ca 1 >> endobj 13 0 obj << /Type /Page /MediaBox [0.000 0.000 595.280 841.890] /Parent 3 0 R /Annots [ 15 0 R 17 0 R ] /Contents 14 0 R >> endobj 14 0 obj << /Length 1215 >> stream 0.000 0.000 0.000 rg BT 35.000 820.168 Td /F1 12.0 Tf [(information, please visit )] TJ ET 0.000 0.000 0.800 rg BT 163.712 820.168 Td /F1 12.0 Tf [(www.treadwelltx.com)] TJ ET 0.000 0.000 0.800 RG 0.6 w 0 J [ ] 0 d 163.712 817.558 m 276.392 817.558 l S 0.000 0.000 0.000 rg BT 276.392 820.168 Td /F1 12.0 Tf [(.)] TJ ET BT 35.000 789.484 Td /F3 14.0 Tf [(Contact)] TJ ET BT 35.000 760.294 Td /F1 12.0 Tf [(Investors:)] TJ ET 0.000 0.000 0.000 RG 35.000 757.684 m 87.020 757.684 l S 0.000 0.000 0.800 rg BT 35.000 745.642 Td /F1 12.0 Tf [(ir@treadwelltx.com)] TJ ET 0.000 0.000 0.800 RG 35.000 743.032 m 137.192 743.032 l S 0.000 0.000 0.000 rg BT 35.000 718.990 Td /F3 12.0 Tf [(Date Created)] TJ ET BT 35.000 704.338 Td /F1 12.0 Tf [(February 3, 2023)] TJ ET q 35.000 701.407 0.000 0.000 re W n Q /GS1 gs /GS2 gs q 35.000 52.000 m 35.000 53.000 l 585.280 53.000 l 585.280 52.000 l 585.280 50.500 l 35.000 50.500 l W n 0.502 0.502 0.502 RG 1.5 w 0 J [ ] 0 d 35.000 51.250 m 585.280 51.250 l S Q /GS1 gs /GS2 gs 0.000 0.000 0.000 rg BT 44.000 31.732 Td /F1 10.0 Tf [(Page 2)] TJ ET q 44.000 17.080 532.280 12.210 re W n BT 258.180 19.522 Td /F1 10.0 Tf [(Treadwell Therapeutics)] TJ ET Q /GS1 gs /GS2 gs endstream endobj 15 0 obj << /Type /Annot /Subtype /Link /F 28 /A 16 0 R /Border [0 0 0] /H /I /Rect [ 163.7120 817.8374 276.3920 830.0474 ] >> endobj 16 0 obj << /Type /Action /S /URI /URI (https://treadwelltx.com/) >> endobj 17 0 obj << /Type /Annot /Subtype /Link /F 28 /A 18 0 R /Border [0 0 0] /H /I /Rect [ 35.0000 743.3106 137.1920 755.5206 ] >> endobj 18 0 obj << /Type /Action /S /URI /URI (mailto:ir@treadwelltx.com) >> endobj xref 0 19 0000000000 65535 f 0000000009 00000 n 0000000074 00000 n 0000000120 00000 n 0000000344 00000 n 0000000373 00000 n 0000000522 00000 n 0000000625 00000 n 0000006563 00000 n 0000006670 00000 n 0000006779 00000 n 0000006892 00000 n 0000006949 00000 n 0000007006 00000 n 0000007137 00000 n 0000008405 00000 n 0000008539 00000 n 0000008615 00000 n 0000008748 00000 n trailer << /Size 19 /Root 1 0 R /Info 5 0 R /ID[] >> startxref 8825 %%EOF